List of Excipients in Branded Drug AMBIEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	AMBIEN	zolpidem tartrate	0024-5401	CELLULOSE, MICROCRYSTALLINE
Sanofi-Aventis US LLC	AMBIEN	zolpidem tartrate	0024-5401	FD&C RED NO. 40
Sanofi-Aventis US LLC	AMBIEN	zolpidem tartrate	0024-5401	FERRIC OXIDE RED
Sanofi-Aventis US LLC	AMBIEN	zolpidem tartrate	0024-5401	HYPROMELLOSE
Sanofi-Aventis US LLC	AMBIEN	zolpidem tartrate	0024-5401	LACTOSE
Sanofi-Aventis US LLC	AMBIEN	zolpidem tartrate	0024-5401	MAGNESIUM STEARATE
Sanofi-Aventis US LLC	AMBIEN	zolpidem tartrate	0024-5401	POLYETHYLENE GLYCOL

Generic Drugs Containing AMBIEN

Company	Ingredient	NDC	Excipient
DIRECT RX	zolpidem tartrate	61919-803	CELLULOSE, MICROCRYSTALLINE
DIRECT RX	zolpidem tartrate	61919-803	HYPROMELLOSE 2910
DIRECT RX	zolpidem tartrate	61919-803	LACTOSE MONOHYDRATE
DIRECT RX	zolpidem tartrate	61919-803	MAGNESIUM STEARATE
DIRECT RX	zolpidem tartrate	61919-803	POLYETHYLENE GLYCOL 400
DIRECT RX	zolpidem tartrate	61919-803	POLYSORBATE 80
DIRECT RX	zolpidem tartrate	61919-803	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in AMBIEN?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	FERRIC OXIDE RED
2	HYPROMELLOSE 2910
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE
2	POLYETHYLENE GLYCOL 400
2	POLYSORBATE 80

AMBIEN Excipient Strategy and Commercial Opportunities for Zolpidem Formulations

Last updated: August 2, 2026

Ambien is a mature zolpidem tartrate franchise with limited brand exclusivity and substantial generic competition. The strongest commercial opportunities are in modified-release excipients, low-dose content uniformity, coating systems, orally disintegrating or sublingual delivery, and controlled-substance handling. The original immediate-release product is a low-barrier generic market, while Ambien CR retains greater technical value because its tablet uses distinct immediate-release and extended-release drug-release phases.

What is Ambien and which formulations are commercially relevant?

Ambien contains zolpidem tartrate, a nonbenzodiazepine sedative-hypnotic approved for short-term treatment of insomnia characterized by difficulty initiating sleep. The immediate-release product is marketed in 5 mg and 10 mg tablets. Ambien CR uses a bilayer modified-release tablet in 6.25 mg and 12.5 mg strengths to provide sleep initiation and sleep maintenance effects. The FDA approved Ambien CR in 2005. [1,2]

Product	Active ingredient	Strengths	Dosage form	Release profile	U.S. regulatory status
Ambien	Zolpidem tartrate	5 mg, 10 mg	Film-coated tablet	Immediate release	FDA-approved NDA product; generic competition
Ambien CR	Zolpidem tartrate	6.25 mg, 12.5 mg	Modified-release bilayer tablet	Immediate-release layer plus extended-release core	FDA-approved NDA product; generic competition
Generic zolpidem	Zolpidem tartrate	Multiple strengths	Tablet, sublingual, oral spray and other forms	Immediate or modified release depending on product	ANDA products approved
Generic zolpidem ER	Zolpidem tartrate	6.25 mg, 12.5 mg	Extended-release tablet	Modified release	ANDA competition

Zolpidem is a Schedule IV controlled substance in the United States. That classification affects packaging, diversion controls, manufacturing security, supply-chain qualification and commercial positioning. [3]

What excipients are used in Ambien tablets?

The immediate-release Ambien tablet uses conventional excipients for compression, disintegration, film coating and tablet robustness. FDA labeling identifies lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hypromellose, magnesium stearate and coating-related materials among the inactive ingredients. Exact excipient quantities are generally not disclosed in the public label. [1]

Ambien CR relies on a more specialized architecture. The product has an outer immediate-release layer and an extended-release core. The excipient strategy therefore has to control both rapid initial dissolution and delayed release during the later portion of the night. The label identifies excipients including lactose monohydrate, microcrystalline cellulose, hypromellose, magnesium stearate and colloidal silicon dioxide, with coating components used to distinguish the product and protect tablet performance. [2]

Functional role of key Ambien excipients

Excipient class	Representative material	Function in zolpidem products	Commercial relevance
Diluent	Lactose monohydrate	Adds tablet mass and supports compression	High-volume, low-margin commodity opportunity
Filler-binder	Microcrystalline cellulose	Improves compactability and tablet strength	Strong opportunity for direct-compression grades
Superdisintegrant	Sodium starch glycolate	Promotes rapid tablet breakup in immediate-release tablets	Important for low-dose, fast-onset products
Matrix former	Hypromellose	Controls hydration and drug diffusion in extended-release systems	Highest-value excipient category for Ambien CR-type products
Lubricant	Magnesium stearate	Reduces sticking and ejection force	Standard but sensitive to over-lubrication
Glidant	Colloidal silicon dioxide	Improves powder flow and blend uniformity	Relevant to low-dose content uniformity
Film former	Hypromellose	Protects and identifies the tablet	Opportunity for ready-to-use coating systems
Opacifier or colorant	Titanium dioxide or approved colorants	Supports appearance and product differentiation	Limited technical differentiation

How does Ambien CR use excipients to control drug release?

Ambien CR is technically more defensible than immediate-release Ambien because its performance depends on a coordinated release system rather than a simple compressed tablet. The formulation must deliver zolpidem quickly enough to support sleep initiation while retaining sufficient drug in the matrix for later release.

The main formulation variables include:

1. Hypromellose grade and viscosity.
2. Polymer concentration in the extended-release core.
3. Core porosity and compression force.
4. Particle-size distribution of zolpidem tartrate.
5. Immediate-release layer composition.
6. Coating weight gain and moisture exposure.
7. Tablet mechanical strength after bilayer compression.

A generic manufacturer cannot rely on excipient identity alone. It must demonstrate pharmaceutical equivalence and bioequivalence under the applicable ANDA pathway. For modified-release products, dissolution profiles, fed and fasting pharmacokinetics, alcohol sensitivity, dose dumping risk and batch-to-batch release control are central development issues. FDA guidance treats modified-release solid oral dosage forms as higher-risk products than conventional immediate-release tablets. [4]

Which excipients offer the best technical opportunity?

The most attractive excipient opportunities are not the basic ingredients used in the immediate-release tablet. They are functional excipient systems that simplify development or improve reproducibility in the modified-release product.

High-value opportunity: hypromellose matrix systems

Hypromellose is the main commercial opportunity for Ambien CR-type products. Suppliers can differentiate through:

• Narrow viscosity distribution.
• Consistent particle morphology.
• Improved dispersion during wet or dry granulation.
• Lower batch-to-batch impact on dissolution.
• Compatibility with direct compression.
• Reduced sensitivity to compression force.
• Better performance across pH and agitation conditions.

A supplier that provides a pre-engineered hypromellose matrix system can reduce formulation screening and scale-up work for generic manufacturers.

Medium-value opportunity: low-dose blend uniformity systems

Zolpidem doses are low relative to total tablet mass. This creates a content-uniformity challenge, especially when the active pharmaceutical ingredient has poor flow or a broad particle-size distribution. Excipient systems based on microcrystalline cellulose, colloidal silicon dioxide and co-processed carriers can improve:

• Active distribution through the blend.
• Flow into the tablet die.
• Segregation resistance.
• Weight variation.
• Compression consistency.

The commercial value is highest when the excipient supplier can provide application data in 5 mg and 6.25 mg dosage strengths.

Medium-value opportunity: rapid-disintegration platforms

For immediate-release zolpidem, rapid disintegration is commercially useful but not by itself a strong barrier. Sodium starch glycolate, crospovidone and low-substituted hydroxypropyl cellulose can support fast tablet breakup. The opportunity is stronger in orally disintegrating tablets, orally disintegrating films and sublingual products, where the formulation must balance speed, taste and mechanical integrity.

Lower-value opportunity: standard tableting excipients

Lactose, conventional microcrystalline cellulose and magnesium stearate are readily sourced. These materials represent recurring volume demand but provide limited pricing power unless the supplier offers a validated grade, regional supply security or a co-processed platform.

What patents protect Ambien and its excipient systems?

The original immediate-release Ambien product has lost practical exclusivity. Generic zolpidem products entered the U.S. market after the expiration of the principal product and formulation protections. Ambien's current commercial position is therefore based on brand recognition, physician familiarity, controlled-substance distribution controls and residual prescribing rather than enforceable core patent exclusivity.

Ambien CR historically relied on patents covering modified-release zolpidem technology and related pharmaceutical compositions. The relevant Orange Book listings should be reviewed by NDA and patent status because a listed patent may cover the dosage form, release profile or composition rather than the active ingredient itself. The FDA Orange Book is the controlling public source for listed patents, expiration dates, pediatric extensions and certifications. [5]

Protection category	Ambien relevance	Current commercial effect
Zolpidem active ingredient	Core compound protection has expired	No meaningful barrier to generic zolpidem
Immediate-release tablet composition	Largely expired or no longer commercially blocking	Low barrier
Ambien CR modified-release formulation	Historically important	Generic manufacturers have developed competing ER products
Method-of-use claims	Sleep-onset and sleep-maintenance treatment claims may be relevant in patents, labeling and litigation	Limited practical blocking value after generic entry
Manufacturing process claims	May cover granulation, bilayer compression or coating	Potentially useful if independently valid and difficult to design around
New delivery systems	Sublingual, buccal, film or abuse-deterrent products may support new patent filings	Primary remaining IP opportunity

Can an excipient combination be patented?

Yes. A conventional excipient such as hypromellose, lactose or microcrystalline cellulose is generally difficult to protect on its own. Patent value can arise from a specific combination or process that produces a defined release profile or manufacturing advantage.

Potential claim categories include:

• A defined polymer grade and concentration range.
• A bilayer tablet with specified release windows.
• A matrix with limits on pore structure or hardness.
• A manufacturing process that reduces dose dumping.
• A coating that changes hydration or drug release.
• A formulation with improved stability under accelerated conditions.
• A sublingual or orally disintegrating formulation with a specified disintegration time.
• A composition that reduces bitterness without delaying zolpidem absorption.

Patentability depends on novelty, nonobviousness, enablement and claim scope. A formulation patent that merely substitutes one routine diluent for another is generally weaker than a patent tied to a measured release profile, unexpected stability result or manufacturing effect.

When does Ambien lose exclusivity and what is the Orange Book status?

Ambien immediate release has already lost market exclusivity. Generic zolpidem is widely available, and no current commercial strategy should assume protection from the original Ambien patents.

Ambien CR also faces generic competition. FDA-approved zolpidem extended-release products have reduced the exclusivity value of the branded modified-release product. The Orange Book should be used to confirm the current status of NDA 021774, including any remaining listed patents, pediatric exclusivity, 30-month litigation stays and therapeutic-equivalence codes. [2,5]

Milestone	Ambien immediate release	Ambien CR
FDA approval	1992	2005
Core patent position	Expired	Historical formulation protection; generic competition exists
Generic pathway	ANDA	ANDA for equivalent extended-release products
Current exclusivity profile	None of practical commercial significance	No broad brand exclusivity blocking generic supply
Main remaining advantage	Brand familiarity and distribution	Modified-release know-how, brand recognition and prescriber familiarity

Which companies are challenging Ambien through generic competition?

Generic zolpidem competition has involved major ANDA manufacturers, including Teva, Mylan, Sandoz, Dr. Reddy's, Torrent and other U.S. and international suppliers. The precise active supplier group changes over time because controlled-substance quotas, product discontinuations, manufacturing economics and wholesaler contracts affect availability.

The relevant competitive distinction is not simply the number of approved ANDAs. It is the number of products actively supplied and substitutable at the pharmacy level. For Ambien CR, the competitive field is narrower because modified-release tablet development, dissolution control and manufacturing scale are more demanding than for immediate-release zolpidem.

What generic entry risks exist for Ambien?

The immediate-release generic entry risk is high because:

• The active ingredient is mature.
• The dosage form is conventional.
• Multiple manufacturers can source standard excipients.
• Pharmacists can substitute therapeutically equivalent products where permitted.
• The product has limited remaining patent protection.

Ambien CR has a higher technical entry barrier but a lower legal barrier than a newly launched protected product. Generic manufacturers must manage:

• Bilayer compression yield.
• Immediate-release and extended-release dissolution targets.
• Tablet robustness.
• Alcohol-induced dose dumping.
• Fed and fasting pharmacokinetic variability.
• Stability of the matrix polymer.
• Controlled-substance manufacturing and distribution requirements.

The highest-risk launch scenario for the brand is a multi-supplier generic market with stable wholesaler inventory and an AB-rated or otherwise substitutable product. The highest-risk scenario for an excipient supplier is commoditization of the standard excipient package without a differentiated performance claim.

What formulation opportunities remain for zolpidem?

Orally disintegrating and sublingual products

Zolpidem delivery can be optimized for patients who have difficulty swallowing or need rapid administration at bedtime. Commercial opportunities include:

• Fast-disintegrating tablets.
• Sublingual tablets.
• Oral films.
• Mucoadhesive dosage forms.
• Low-moisture packaging systems.
• Taste-masked multiparticulates.

The excipient priorities are rapid wetting, low residual bitterness, adequate mechanical strength, low friability and protection from moisture. Zolpidem sublingual products already exist in the U.S. market, including Intermezzo, which demonstrates that alternative delivery can support a separate product concept. [6]

Abuse-deterrent or controlled-release systems

Zolpidem is a controlled substance, but it is not generally positioned in the same abuse-deterrent category as opioid products. A new formulation could seek differentiation through:

• Reduced crushing or extraction.
• Polymer matrices resistant to rapid release.
• Non-crushable multiparticulates.
• Tamper-evident packaging.
• Dose-limiting delivery systems.

Such products would face substantial clinical, regulatory and commercial hurdles. An excipient system alone would not establish abuse-deterrent labeling. FDA guidance requires product-specific evidence linking formulation design to tamper resistance and abuse-related performance. [7]

Pediatric and geriatric formulations

Pediatric use is constrained by safety and labeling considerations. Geriatric formulations have a more practical commercial rationale because zolpidem exposure and adverse-effect risk require lower dosing in older adults. Opportunity areas include:

• Accurate low-dose units.
• Scored or divisible tablets where appropriate.
• Low-swallowing-burden dosage forms.
• Reduced excipient load.
• Sugar-free and low-lactose alternatives.
• Packaging that limits accidental access.

Any such product would require alignment with FDA labeling, safety data and controlled-substance controls.

How strong is the Ambien patent estate?

The Ambien patent estate is weak for the immediate-release product and moderate from a technical standpoint for modified-release and alternative-delivery formulations. Its commercial value is not concentrated in a live composition-of-matter patent.

Estate component	Patent strength	Commercial assessment
Original zolpidem molecule	Low today	Expired core protection
Immediate-release tablet	Low	Easy generic substitution
Ambien CR release architecture	Moderate technical complexity	More difficult to reproduce consistently
New excipient combinations	Variable	Strong only with unexpected performance or process advantages
Sublingual and oral film delivery	Moderate	Potential lifecycle-management route
Abuse-deterrent delivery	Potentially high but execution-dependent	Requires regulatory and clinical support
Manufacturing know-how	Moderate	Can create practical barriers without broad exclusivity

Geographic coverage is also limited by the jurisdiction-specific nature of pharmaceutical patents and regulatory approvals. U.S. patents do not establish protection in Europe, Japan, Canada or emerging markets. Suppliers and licensees should analyze national patent registers, local generic approvals and controlled-substance rules separately.

What licensing deals and commercial partnerships matter?

The central historical commercial relationship was the development and marketing of Ambien by Searle and later Sanofi. The product is now a mature Sanofi-associated brand, while generic zolpidem is supplied by multiple manufacturers. Public disclosures do not establish a major current excipient-specific licensing platform tied to Ambien.

The most realistic licensing targets are:

• Co-processed direct-compression excipients.
• Hypromellose matrix technologies.
• Taste-masking systems.
• Oral-film manufacturing platforms.
• Bilayer tableting technology.
• Moisture-protective packaging.
• Controlled-substance diversion-control systems.

An excipient supplier seeking commercial access should license a measurable formulation advantage, not merely a known inactive ingredient. The strongest package would include comparative dissolution data, scale-up data, stability results, tabletability data and a regulatory support file.

What is the FDA regulatory status of Ambien?

Ambien and Ambien CR are FDA-approved prescription products. Zolpidem products are subject to controlled-substance requirements and FDA safety labeling. In 2013, FDA required lower recommended doses for women because zolpidem clearance was slower on average in women, increasing next-morning impairment risk. [8]

FDA labeling also includes warnings concerning complex sleep behaviors, central nervous system depression, next-day impairment and use with other sedatives. These safety requirements affect formulation strategy because a faster or more prolonged release profile can change exposure and tolerability.

A new zolpidem formulation would likely require one of the following:

• ANDA, if it is pharmaceutically equivalent to a reference listed drug.
• 505(b)(2) application, if it relies on an approved product but changes the dosage form, route, strength or release profile.
• Full NDA, if the product contains a materially new active ingredient or requires a new clinical development program.

What is the commercial opportunity for excipient suppliers?

The commercial opportunity is segmented by product type.

Opportunity	Demand outlook	Margin potential	Entry barrier
Standard lactose and MCC for generic zolpidem IR	Stable, high volume	Low	Low
Superdisintegrants for rapid-release tablets	Stable	Low to moderate	Low
Hypromellose for zolpidem ER matrices	Stable, specialized	Moderate to high	Moderate
Co-processed low-dose blend systems	Growing niche	Moderate to high	Moderate
Taste-masking systems	Niche	High	Moderate
Oral-film excipients	Selective	High	High
Abuse-deterrent matrix platforms	Limited but strategic	High	High
Regulatory and formulation support services	Recurring	High	Moderate

Revenue exposure for Sanofi is difficult to isolate because public financial reporting generally does not disclose Ambien revenue as a separate current line item. The commercial exposure is more material for generic manufacturers and excipient suppliers that compete for recurring volume in zolpidem tablets and modified-release products.

The best near-term strategy is to sell a performance-qualified excipient system to generic zolpidem ER manufacturers. The best long-term strategy is to support a 505(b)(2) lifecycle product with a new delivery profile, provided the formulation produces a clinically meaningful advantage and supports defensible patent claims.

Key Takeaways

• Ambien immediate release is an off-patent, highly substitutable generic market.
• Ambien CR retains greater formulation complexity because it combines immediate and extended release in a bilayer tablet.
• Hypromellose matrix systems are the most commercially valuable excipient opportunity for Ambien CR-type products.
• Low-dose blend uniformity, fast disintegration and taste masking are relevant lifecycle-management priorities.
• Standard lactose, microcrystalline cellulose and magnesium stearate are volume opportunities with limited differentiation.
• Excipient patents are strongest when tied to unexpected dissolution, stability, manufacturability or tamper-resistance results.
• Zolpidem's Schedule IV status creates supply-chain, packaging and manufacturing requirements.
• New oral-film, sublingual and abuse-deterrent products would likely require 505(b)(2) development rather than simple generic substitution.
• Current competitive risk is highest for Ambien immediate release and moderate to high for Ambien CR.
• No separately reported current Ambien revenue line allows a precise brand revenue-exposure estimate from public filings.

FAQs

What is the best excipient for an Ambien CR generic?

Hypromellose is the key matrix-forming excipient, but the optimal grade and concentration depend on the target dissolution profile, tablet hardness, drug loading and manufacturing process.

Can lactose-free zolpidem tablets be developed?

Yes. Lactose can be replaced with materials such as mannitol, dibasic calcium phosphate, sorbitol or co-processed excipients, subject to compatibility, compression, stability and bioequivalence requirements.

Is zolpidem a biologic with biosimilar risk?

No. Zolpidem is a small-molecule drug. Biosimilar pathways do not apply. Competition arises through generic ANDA products or, for materially different formulations, 505(b)(2) products.

Can an excipient supplier obtain patent protection for a zolpidem formulation?

Yes, if the formulation or process meets patentability requirements and provides a defined technical result. A routine substitution of one standard filler for another is unlikely to create strong protection.

Which Ambien lifecycle strategy has the highest commercial potential?

A modified-release, sublingual or taste-masked product with a clinically relevant use advantage has greater potential than another conventional immediate-release tablet. The product must also support a credible regulatory pathway and defensible formulation claims.

References

1. U.S. Food and Drug Administration. (2023). Ambien (zolpidem tartrate) tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Ambien CR (zolpidem tartrate extended-release tablets): Prescribing information. FDA.

3. U.S. Drug Enforcement Administration. (2024). Controlled substances schedules. U.S. Department of Justice.

4. U.S. Food and Drug Administration. (2019). Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. FDA.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

6. U.S. Food and Drug Administration. (2023). Intermezzo (zolpidem tartrate) sublingual tablets: Prescribing information. FDA.

7. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. FDA.

8. U.S. Food and Drug Administration. (2013). FDA requiring lower recommended dose for certain sleep drugs containing zolpidem. FDA.